{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-351399","form_type":"8-K","ticker":"NERV","cik":"0001598646","company_name":"Minerva Neurosciences, Inc.","filed_at":"2021-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.217760+00:00","generated_at":"2026-06-28T02:49:54.012563+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roluperidone phase 3 trial: primary endpoint missed in ITT (p=0.064) but significant in mITT; PSP improved","bullets":["NSFS (primary) for roluperidone 64mg vs placebo: p≤0.064 (ITT), p≤0.044 (mITT).","PSP total score (key secondary) significantly improved for 64mg vs placebo: p≤0.021 (ITT), p≤0.017 (mITT).","Relapse rate during open-label extension: 6% (64mg) and 9% (32mg) over one year.","Trial enrolled 513 schizophrenia patients with moderate to severe negative symptoms; monotherapy design.","Results presented at ACNP meeting December 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-351399","json":"https://secwatch.observer/filing/0001193125-21-351399.json","markdown":"https://secwatch.observer/filing/0001193125-21-351399.md","text":"https://secwatch.observer/filing/0001193125-21-351399.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1598646/000119312521351399/0001193125-21-351399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1598646/000119312521351399/d74277d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:49:54.012563+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}